Comparison of Individualized Sodium Management Versus Standard Treatment in Hemodialysis - Trial NCT06341452
Access comprehensive clinical trial information for NCT06341452 through Pure Global AI's free database. This phase not specified trial is sponsored by Fresenius Medical Care Deutschland GmbH and is currently Not yet recruiting. The study focuses on End Stage Renal Disease. Target enrollment is 130 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Hemodialysis or Hemodiafiltration either with sodium zero-diffusive treatment or standard treatment without sodium-control
Interventional
device
Sponsor & Location
Fresenius Medical Care Deutschland GmbH
Timeline & Enrollment
N/A
Jun 01, 2024
Dec 01, 2025
Primary Outcome
Interdialytic weight gain,Intradialytic hemodynamic stability,Intradialytic hemodynamic stability,Intradialytic morbid events,Fluid status,Fluid status
Summary
The SODIAH study is designed with the aim to assess the impact of isonatremic dialysis on
 interdialytic weight gain, fluid status, intradialytic hemodynamic stability, and incidence
 of intradialytic morbid events in dialysis patients. The study will be comparing the Na
 management option on the 6008 HD dialysis machines with the same machine without the Na
 management option turned on. Relevant performance and clinical data will be collected as well
 as information on patients' quality of life and wellbeing.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06341452
Device Trial